$EQ
Equillium, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022017399 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.466M $4.064M $3.517M
YoY Change 54.21% 42.2% 20.45%
% of Gross Profit
Research & Development $8.771M $9.488M $10.76M
YoY Change 25.93% 58.53% 83.04%
% of Gross Profit
Depreciation & Amortization $30.00K $31.00K $25.00K
YoY Change 57.89% 121.43% 25.0%
% of Gross Profit
Operating Expenses $13.24M $13.55M $37.33M
YoY Change 34.24% 53.25% 329.32%
Operating Profit -$13.24M -$13.55M -$37.33M
YoY Change 34.24% 53.25% 329.32%
Interest Expense -$137.0K -$195.0K -$230.0K
YoY Change -46.9% -24.12% -8.0%
% of Operating Profit
Other Income/Expense, Net -$418.0K -$577.0K -$88.00K
YoY Change -0.71% 83.17% -70.27%
Pretax Income -$13.66M -$14.13M -$37.42M
YoY Change 32.8% 54.28% 316.21%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.66M -$14.13M -$37.42M
YoY Change 32.8% 54.28% 316.16%
Net Earnings / Revenue
Basic Earnings Per Share -$0.40 -$0.41 -$1.17
Diluted Earnings Per Share -$0.40 -$0.41 -$1.174M
COMMON SHARES
Basic Shares Outstanding 34.35M 34.29M 34.28M
Diluted Shares Outstanding 34.35M 34.29M 31.87M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.52M $57.56M $68.82M
YoY Change -50.91% -41.05% -33.87%
Cash & Equivalents $25.73M $23.81M $26.24M
Short-Term Investments $18.79M $33.75M $42.58M
Other Short-Term Assets $2.254M $2.920M $3.262M
YoY Change 52.71% 51.85% 30.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $46.78M $60.48M $72.09M
YoY Change -49.25% -39.25% -32.39%
LONG-TERM ASSETS
Property, Plant & Equipment $423.0K $451.0K $464.0K
YoY Change 74.07% 77.56% 108.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $113.0K $121.0K $145.0K
YoY Change 98.25% 611.76%
Total Long-Term Assets $1.855M $1.990M $2.150M
YoY Change 518.33% 634.32% 864.13%
TOTAL ASSETS
Total Short-Term Assets $46.78M $60.48M $72.09M
Total Long-Term Assets $1.855M $1.990M $2.150M
Total Assets $48.63M $62.47M $74.24M
YoY Change -47.41% -37.43% -30.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.469M $5.091M $4.210M
YoY Change -7.49% 180.34% 81.15%
Accrued Expenses $6.326M $5.377M $5.626M
YoY Change 63.93% 69.94% 116.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.714M $4.286M $2.857M
YoY Change 357.12% 14.28%
Total Short-Term Liabilities $14.93M $15.19M $13.11M
YoY Change 91.95% 204.98% 76.8%
LONG-TERM LIABILITIES
Long-Term Debt $4.616M $5.992M $7.370M
YoY Change -47.98% -40.48% -1.81%
Other Long-Term Liabilities $925.0K $1.025M $1.122M
YoY Change 5341.18% 5929.41% 3105.71%
Total Long-Term Liabilities $4.616M $5.992M $7.370M
YoY Change -48.08% -40.58% -2.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.93M $15.19M $13.11M
Total Long-Term Liabilities $4.616M $5.992M $7.370M
Total Liabilities $20.47M $22.21M $21.61M
YoY Change 22.82% 47.4% 44.44%
SHAREHOLDERS EQUITY
Retained Earnings -$175.2M -$161.5M -$147.4M
YoY Change 76.31% 81.34% 84.44%
Common Stock $203.1M $201.9M $200.5M
YoY Change 15.93% 16.02% 16.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.16M $40.27M $52.63M
YoY Change
Total Liabilities & Shareholders Equity $48.63M $62.47M $74.24M
YoY Change -47.41% -37.43% -30.52%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$13.66M -$14.13M -$37.42M
YoY Change 32.8% 54.28% 316.16%
Depreciation, Depletion And Amortization $30.00K $31.00K $25.00K
YoY Change 57.89% 121.43% 25.0%
Cash From Operating Activities -$13.06M -$11.26M -$12.13M
YoY Change 86.38% 60.89% 52.74%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$54.00K $223.0K
YoY Change -100.0% 134.78%
Acquisitions
YoY Change
Other Investing Activities $15.00M $8.745M -$11.76M
YoY Change 42.83% -69.83% -342.02%
Cash From Investing Activities $15.00M $8.691M -$11.99M
YoY Change 43.29% -70.0% -346.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 141.0K 0.000
YoY Change -100.0% -79.91% -100.0%
NET CHANGE
Cash From Operating Activities -13.06M -11.26M -12.13M
Cash From Investing Activities 15.00M 8.691M -11.99M
Cash From Financing Activities 0.000 141.0K 0.000
Net Change In Cash 1.935M -2.427M -24.12M
YoY Change -46.72% -110.71% -189.74%
FREE CASH FLOW
Cash From Operating Activities -$13.06M -$11.26M -$12.13M
Capital Expenditures $0.00 -$54.00K $223.0K
Free Cash Flow -$13.06M -$11.21M -$12.36M
YoY Change 87.28% 60.65% 55.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Small Business
EntitySmallBusiness
true
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001746466
CY2022Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
CY2021Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38692
dei Entity Registrant Name
EntityRegistrantName
EQUILLIUM, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1554746
dei Entity Address Address Line1
EntityAddressAddressLine1
2223 Avenida de la Playa
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 105
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34352084
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23808000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50366000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
33754000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
30345000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2920000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2659000
us-gaap Share Based Compensation
ShareBasedCompensation
2108000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
60482000
dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
412-5302
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
EQ
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-161523000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109977000
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5985000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
20251000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
83370000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1418000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1645000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
451000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
237000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
121000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
153000
CY2022Q2 us-gaap Assets
Assets
62472000
CY2021Q4 us-gaap Assets
Assets
85405000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5091000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1225000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5377000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5886000
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
4286000
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1428000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
434000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
376000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15188000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8915000
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
5992000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8750000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1025000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1235000
CY2022Q2 us-gaap Liabilities
Liabilities
22205000
CY2021Q4 us-gaap Liabilities
Liabilities
18900000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34352084
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34352084
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29455668
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29455668
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
201936000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
176618000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-149000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
40267000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
66505000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62472000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85405000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9488000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
305000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11865000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
46000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51557000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
23049000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4064000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2858000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7581000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5673000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
13552000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
8843000
us-gaap Operating Expenses
OperatingExpenses
50881000
us-gaap Operating Expenses
OperatingExpenses
17538000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13552000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8843000
us-gaap Operating Income Loss
OperatingIncomeLoss
-50881000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17538000
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
259000
CY2021Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
270000
us-gaap Interest Expense Debt
InterestExpenseDebt
515000
us-gaap Interest Expense Debt
InterestExpenseDebt
541000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
64000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
us-gaap Investment Income Interest
InvestmentIncomeInterest
90000
us-gaap Investment Income Interest
InvestmentIncomeInterest
39000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-382000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-58000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-240000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-109000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-577000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-315000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-665000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-611000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14129000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-9158000
us-gaap Net Income Loss
NetIncomeLoss
-51546000
us-gaap Net Income Loss
NetIncomeLoss
-18149000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-54000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-5000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-234000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-8000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
359000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
51000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
223000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
96000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
88000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13824000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9112000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18061000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34292642
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34292642
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29076562
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29076562
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33085917
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33085917
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28205805
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28205805
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
69854000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
18000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1044000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
42000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8991000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
91880000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
127000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
796000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
18000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1064000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
46000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-9158000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
84773000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
66505000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
18000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1298000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-316000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37417000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
52630000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
141000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
18000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1302000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
305000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14129000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
40267000
us-gaap Profit Loss
ProfitLoss
-51546000
us-gaap Profit Loss
ProfitLoss
-18149000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
23049000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
56000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
34000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-245000
us-gaap Share Based Compensation
ShareBasedCompensation
2600000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-100000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-107000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
100000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
126000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-73000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-205000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
220000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1252000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3623000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-971000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1447000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
350000
eq Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
-74000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23393000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14938000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
277000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
14962000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
7605000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
11245000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
41455000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3294000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33827000
eq Proceeds From Registered Direct Offering Net Of Offering Costs
ProceedsFromRegisteredDirectOfferingNetOfOfferingCosts
29909000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
626000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
141000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
127000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
141000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30662000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-12000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-8000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26558000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
49543000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50366000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23982000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23808000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73525000
eq Unsettled Stock Option Exercises
UnsettledStockOptionExercises
174000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
25000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-03-16
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
57600000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-400000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-200000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-100000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
34040000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
286000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
33754000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
30397000
CY2022Q2 eq Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
976000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
1241000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the condensed consolidated financial statements and accompanying notes. Significant estimates in the Company’s condensed consolidated financial statements relate to accrued research and development expense and the valuation of equity awards. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company’s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Off-Balance Sheet Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in which the majority of deposits are in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company’s investment policy includes guidelines for the quality of the related institutions and financial instruments and defines allowable investments that the Company may invest in, which the Company believes minimizes the exposure to concentration of credit risk.</span></p>
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
52000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
30345000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
507000
CY2022Q2 eq Business Combination Acquired In Process Research And Development
BusinessCombinationAcquiredInProcessResearchAndDevelopment
23049000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6669966
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5206092
CY2022Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
33754000
CY2021Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
30345000
CY2022Q2 us-gaap Notes Payable
NotesPayable
10300000
CY2021Q4 us-gaap Notes Payable
NotesPayable
10200000
CY2022Q2 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2021Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
28000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets
6000
CY2019Q3 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2024-06-01
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
734000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
265000
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1887000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2511000
CY2022Q2 eq Accrued Clinical Studies
AccruedClinicalStudies
2835000
CY2021Q4 eq Accrued Clinical Studies
AccruedClinicalStudies
2627000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
252000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
245000
CY2022Q2 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
334000
CY2021Q4 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
432000
CY2022Q2 us-gaap Interest Payable Current
InterestPayableCurrent
69000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
71000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5377000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5886000
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
700000
CY2022Q2 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal Remainder Of Fiscal Year
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1429000
CY2022Q2 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Two
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearTwo
5714000
CY2022Q2 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Three
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearThree
3357000
CY2022Q2 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFee
10500000
CY2022Q2 eq Unaccreted Liability For Final Payment Fee
UnaccretedLiabilityForFinalPaymentFee
131000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
91000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
10278000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
4286000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5992000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1418000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
434000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1025000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1459000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y5M8D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
us-gaap Operating Lease Payments
OperatingLeasePayments
183000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
283000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
494000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
492000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
219000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
169000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
28000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1685000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
226000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1459000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34352084
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29455668
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
9700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1302000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1064000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2600000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2108000
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8241001
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6549848

Files In Submission

Name View Source Status
0000950170-22-017399-index-headers.html Edgar Link pending
0000950170-22-017399-index.html Edgar Link pending
0000950170-22-017399.txt Edgar Link pending
0000950170-22-017399-xbrl.zip Edgar Link pending
eq-20220630.htm Edgar Link pending
eq-20220630.xsd Edgar Link pending
eq-ex31_1.htm Edgar Link pending
eq-ex31_2.htm Edgar Link pending
eq-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
eq-20220630_pre.xml Edgar Link unprocessable
eq-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
eq-20220630_cal.xml Edgar Link unprocessable
eq-20220630_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
eq-20220630_def.xml Edgar Link unprocessable